2.1 Eligibility criteria
Inclusion in this meta-analysis was restricted to studies that met all the following eligibility criteria: (1) randomized controlled trials (RCTs); (2) comparing FGF21 analogs to placebo; (3) enrolling patients with NASH; and (4) reporting at least one of the outcomes of interest. There was no restriction on follow-up, as the preliminary literature review did not find substantial heterogeneity in follow-up between different studies. We excluded studies with (1) no control group; (2) population overlap; or (3) in patients without NASH.